PerfinityiDP System
Shimadzu introduces the PerfinityiDP (integrated Digestion Platform) system. This online enzyme digestion HPLC system fully automates all processes from the enzymatic digestion of protein samples to the HPLC analysis of digested peptides
PerfinityiDP System
Shimadzu introduces the PerfinityiDP* (integrated Digestion Platform) system. This online enzyme digestion HPLC system fully automates all processes from the enzymatic digestion of protein samples to the HPLC analysis of digested peptides.
The PerfinityiDP uses a high-efficiency immobilized trypsin column for the online enzymatic digestion of proteins, it permits the online enzymatic digestion of proteins in less than one minute. The system iDP improves the analysis throughput by performing parallel processing of the stages from trypsin digestion to concentration in the desalting column and the stages from elution out of the desalting column to HPLC analysis.
The easy-to-use software supports method creation and selection for the series of processes from trypsin digestion to desalting and HPLC analysis.
An LC/MS can be added as a detector to automate the entire process up to analysis. Compared to conventional manual operations, the iDP offers more uniform control across the board and improves accuracy.
For more information please visit www.shimadzu.eu.
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
